With the upcoming implementation of the new Cancer Drug List in September 2022, there have been heated debates about the impact of this policy on cancer patients. The list outlines the outpatient cancer drugs and clinical indications that are claimable under MediShield Life and MediSave.
The issues raised include off-label drug usage and significant price discrepancies between public and private drugs. Will shifting cancer care back to public centres truly address the crux of these issues in a sustainable manner? And how can the private sector also play a vital role in sustaining a robust healthcare delivery and financing ecosystem?
Hear from Associate Professor Wee Hwee Lin, Director of Centre for Health Intervention and Policy Evaluation Research at the NUS Saw Swee Hock School of Public Health, as she weighs in.
Read more below:
- Shifting cancer care back to public hospitals is no cure, The Straits Times, 14 July 2022